Livia Casciola-Rosen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4393376/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cleavage by Granzyme B Is Strongly Predictive of Autoantigen Status. Journal of Experimental Medicine, 1999, 190, 815-826.	4.2	477
2	The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): AÂretrospective study. Journal of the American Academy of Dermatology, 2011, 65, 25-34.	0.6	476
3	Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. Journal of Experimental Medicine, 2005, 201, 591-601.	4.2	351
4	Autoantigens as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune disease. Cell Death and Differentiation, 1999, 6, 6-12.	5.0	344
5	Most Patients With Cancerâ€Associated Dermatomyositis Have Antibodies to Nuclear Matrix Protein NXPâ€⊋ or Transcription Intermediary Factor 1γ. Arthritis and Rheumatism, 2013, 65, 2954-2962.	6.7	325
6	Granzyme B Directly and Efficiently Cleaves Several Downstream Caspase Substrates: Implications for CTL-Induced Apoptosis. Immunity, 1998, 8, 451-460.	6.6	305
7	Histidyl–tRNA Synthetase and Asparaginyl–tRNA Synthetase, Autoantigens in Myositis, Activate Chemokine Receptors on T Lymphocytes and Immature Dendritic Cells. Journal of Experimental Medicine, 2002, 196, 781-791.	4.2	246
8	Anti–Melanoma Differentiation–Associated Protein 5–Associated Dermatomyositis: Expanding the Clinical Spectrum. Arthritis Care and Research, 2013, 65, 1307-1315.	1.5	241
9	Scleroderma Autoantigens Are Uniquely Fragmented by Metal-catalyzed Oxidation Reactions: Implications for Pathogenesis. Journal of Experimental Medicine, 1997, 185, 71-80.	4.2	198
10	Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis and Rheumatism, 2010, 62, 2787-2795.	6.7	180
11	239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14–16 December 2018. Neuromuscular Disorders, 2020, 30, 70-92.	0.3	148
12	Clinical Profile of Anti-PL-12 Autoantibody. Chest, 2009, 135, 1550-1556.	0.4	145
13	Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. Journal of the American Academy of Dermatology, 2015, 72, 449-455.	0.6	143
14	Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 17609-17614.	3.3	140
15	Macromolecular substrates for the ICE-like proteases during apoptosis. , 1997, 64, 50-54.		134
16	Antinuclear Matrix Protein 2 Autoantibodies and Edema, Muscle Disease, and Malignancy Risk in Dermatomyositis Patients. Arthritis Care and Research, 2017, 69, 1771-1776.	1.5	130
17	Myositis autoantibodies. Current Opinion in Rheumatology, 2012, 24, 602-608.	2.0	120
18	Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis. Arthritis and Rheumatism, 2008, 58, 1958-1967.	6.7	119

LIVIA CASCIOLA-ROSEN

#	Article	IF	CITATIONS
19	Molecular Subsetting of Interferon Pathways in Sjögren's Syndrome. Arthritis and Rheumatology, 2015, 67, 2437-2446.	2.9	115
20	Longitudinal Course of Disease in a Large Cohort of Myositis Patients With Autoantibodies Recognizing the Signal Recognition Particle. Arthritis Care and Research, 2017, 69, 263-270.	1.5	108
21	Sequential activation of three distinct ICE-like activities in Fas-ligated Jurkat cells. FEBS Letters, 1996, 390, 299-303.	1.3	105
22	Identification of Clinical Features and Autoantibodies Associated With Calcinosis in Dermatomyositis. JAMA Dermatology, 2014, 150, 724.	2.0	96
23	Cutaneous and Systemic Findings Associated With Nuclear Matrix Protein 2 Antibodies in Adult Dermatomyositis Patients. Arthritis Care and Research, 2017, 69, 1909-1914.	1.5	95
24	The Inhibition of Apoptosis in Myositis and in Normal Muscle Cells. Journal of Immunology, 2000, 164, 5459-5465.	0.4	93
25	Mouse and Human Granzyme B Have Distinct Tetrapeptide Specificities and Abilities to Recruit the Bid Pathway. Journal of Biological Chemistry, 2007, 282, 4545-4552.	1.6	93
26	Examination of Autoantibody Status and Clinical Features Associated With Cancer Risk and Cancerâ€Associated Scleroderma. Arthritis and Rheumatology, 2015, 67, 1053-1061.	2.9	93
27	Study of Tofacitinib in Refractory Dermatomyositis: An Openâ€Label Pilot Study of Ten Patients. Arthritis and Rheumatology, 2021, 73, 858-865.	2.9	93
28	Review: Cancerâ€Induced Autoimmunity in the Rheumatic Diseases. Arthritis and Rheumatology, 2015, 67, 317-326.	2.9	90
29	Mechanisms of Disease: autoantigens as clues to the pathogenesis of myositis. Nature Clinical Practice Rheumatology, 2008, 4, 201-209.	3.2	89
30	Caspase-mediated proteolysis during apoptosis: insights from apoptotic neutrophils. FEBS Letters, 1998, 422, 179-184.	1.3	85
31	Clearing the way to mechanisms of autoimmunity. Nature Medicine, 2001, 7, 664-665.	15.2	85
32	Systematic autoantigen analysis identifies a distinct subtype of scleroderma with coincident cancer. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7526-E7534.	3.3	75
33	A Novel Dermato-Pulmonary Syndrome Associated With MDA-5 Antibodies. Medicine (United States), 2012, 91, 220-228.	0.4	74
34	Inflammatory myopathy associated with anti-mitochondrial antibodies: A distinct phenotype with cardiac involvement. Seminars in Arthritis and Rheumatism, 2018, 47, 552-556.	1.6	73
35	Novel fragments of the Sjzgren's syndrome autoantigens ?-fodrin and type 3 muscarinic acetylcholine receptor generated during cytotoxic lymphocyte granule-induced cell death. Arthritis and Rheumatism, 2001, 44, 2376-2386.	6.7	67
36	More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Rheumatology, 2017, 56, kew470.	0.9	67

LIVIA CASCIOLA-ROSEN

#	Article	IF	CITATIONS
37	Brief Report: Anti–RNPCâ€3 Antibodies As a Marker of Cancerâ€Associated Scleroderma. Arthritis and Rheumatology, 2017, 69, 1306-1312.	2.9	61
38	Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2018-212999.	0.5	60
39	Spectrum of Muscle Histopathologic Findings in Fortyâ€Two Scleroderma Patients With Weakness. Arthritis Care and Research, 2015, 67, 1416-1425.	1.5	56
40	Autoantigens as Partners in Initiation and Propagation of Autoimmune Rheumatic Diseases. Annual Review of Immunology, 2016, 34, 395-420.	9.5	49
41	Expression of the Dermatomyositis Autoantigen Transcription Intermediary Factor 1Î ³ in Regenerating Muscle. Arthritis and Rheumatology, 2015, 67, 266-272.	2.9	42
42	Ovoid Palatal Patch in Dermatomyositis. JAMA Dermatology, 2016, 152, 1049.	2.0	40
43	Myositis-specific autoantibodies are specific for myositis compared to genetic muscle disease. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e172.	3.1	38
44	Association of Antibodies to Interferonâ€Inducible Proteinâ€16 With Markers of More Severe Disease in Primary Sjögren's Syndrome. Arthritis Care and Research, 2016, 68, 254-260.	1.5	38
45	Selective cleavage of nucleolar autoantigen B23 by granzyme B in differentiated vascular smooth muscle cells: Insights into the association of specific autoantibodies with distinct disease phenotypes. Arthritis and Rheumatism, 2004, 50, 233-241.	6.7	37
46	Autoantibodies to transcription intermediary factor 1 in dermatomyositis shed insight into the cancer–myositis connection. Arthritis and Rheumatism, 2012, 64, 346-349.	6.7	36
47	Muscular and extramuscular features of myositis patients with anti-U1-RNP autoantibodies. Neurology, 2019, 92, e1416-e1426.	1.5	36
48	Association of Fibrosing Myopathy in Systemic Sclerosis and Higher Mortality. Arthritis Care and Research, 2017, 69, 1764-1770.	1.5	35
49	Association Between Autoantibody Phenotype and Cutaneous Adverse Reactions to Hydroxychloroquine in Dermatomyositis. JAMA Dermatology, 2018, 154, 1199.	2.0	34
50	Protective Effect Against Cancer of Antibodies to the LargeÂSubunits of Both <scp>RNA</scp> Polymerases I and <scp>III</scp> in Scleroderma. Arthritis and Rheumatology, 2019, 71, 1571-1579.	2.9	34
51	Myositis Autoantibodies: A Comparison of Results From the Oklahoma Medical Research Foundation Myositis Panel to the Euroimmun Research Line Blot. Arthritis and Rheumatology, 2020, 72, 192-194.	2.9	34
52	PUF60: a prominent new target of the autoimmune response in dermatomyositis and Sjögren's syndrome. Annals of the Rheumatic Diseases, 2016, 75, 1145-1151.	0.5	33
53	Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis. JAMA Dermatology, 2018, 154, 44.	2.0	32
54	Anti– <scp>RNPC</scp> â€3 (U11/U12) Antibodies in Systemic Sclerosis in Patients With Moderateâ€to‣eve Gastrointestinal Dysmotility. Arthritis Care and Research, 2019, 71, 1164-1170.	ere 1.5	28

4

LIVIA CASCIOLA-ROSEN

#	Article	IF	CITATIONS
55	A North American Cohort of Anti‧AE Dermatomyositis: Clinical Phenotype, Testing, and Review of Cases. ACR Open Rheumatology, 2021, 3, 287-294.	0.9	28
56	Immune responses to CCAR1 and other dermatomyositis autoantigens are associated with attenuated cancer emergence. Journal of Clinical Investigation, 2022, 132, .	3.9	26
57	Performance of the 2017 European Alliance of Associations for Rheumatology/American College of Rheumatology Classification Criteria for Idiopathic Inflammatory Myopathies in Patients With <scp>Myositisâ€5pecific</scp> Autoantibodies. Arthritis and Rheumatology, 2022, 74, 508-517.	2.9	24
58	lgM anti-ACE2 autoantibodies in severe COVID-19 activate complement and perturb vascular endothelial function. JCI Insight, 2022, 7, .	2.3	23
59	The DNA sensors AIM2 and IFI16 are SLE autoantigens that bind neutrophil extracellular traps. ELife, 0, 11, .	2.8	23
60	Mechanistic and clinical insights at the scleroderma-cancer interface. Journal of Scleroderma and Related Disorders, 2017, 2, 153-159.	1.0	21
61	An update on autoantibodies in scleroderma. Current Opinion in Rheumatology, 2018, 30, 548-553.	2.0	21
62	IFI16 filament formation in salivary epithelial cells shapes the anti-IFI16 immune response in Sjögren's syndrome. JCI Insight, 2018, 3, .	2.3	21
63	The lung as a possible target for the immune reaction in myositis. Arthritis Research and Therapy, 2011, 13, 230.	1.6	20
64	Cancer in Systemic Sclerosis: Analysis of Antibodies Against Components of the Th/To Complex. Arthritis and Rheumatology, 2021, 73, 315-323.	2.9	19
65	Autoantibodies targeting telomere-associated proteins in systemic sclerosis. Annals of the Rheumatic Diseases, 2021, 80, 912-919.	0.5	19
66	Cancer and Scleroderma. Rheumatic Disease Clinics of North America, 2020, 46, 551-564.	0.8	14
67	Longâ€ŧerm extension study of tofacitinib in refractory dermatomyositis. Arthritis and Rheumatology, 2022, 74, 371-372.	2.9	14
68	Centromere protein C is a target of autoantibodies in Sjögren's syndrome and is uniformly associated with antibodies to Ro and La. Journal of Rheumatology, 2004, 31, 1121-5.	1.0	14
69	Anti–Interferonâ€Inducible Protein 16 Antibodies Associate With Digital Gangrene in Patients With Scleroderma. Arthritis and Rheumatology, 2016, 68, 1262-1271.	2.9	13
70	Isolated elevation of aldolase in the serum of myositis patients: a potential biomarker of damaged early regenerating muscle cells. Clinical and Experimental Rheumatology, 2012, 30, 548-53.	0.4	13
71	Distinct dermatomyositis populations are detected with different autoantibody assay platforms. Clinical and Experimental Rheumatology, 2019, 37, 1048-1051.	0.4	12
72	Identification of novel autoantigens by a triangulation approach. Journal of Immunological Methods, 2012, 385, 35-44.	0.6	11

#	Article	IF	CITATIONS
73	Enrichment of Scleroderma Vascular Disease–Associated Autoantigens in Endothelial Lineage Cells. Arthritis and Rheumatology, 2016, 68, 2540-2549.	2.9	10
74	Evaluation of cancer-associated myositis and scleroderma autoantibodies in breast cancer patients without rheumatic disease. Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 71-74.	0.4	10
75	Autoimmune myositis: new concepts for disease initiation and propagation. Current Opinion in Rheumatology, 2005, 17, 699-700.	2.0	9
76	Association of systemic lupus erythematosus autoantibody diversity with breast cancer protection. Arthritis Research and Therapy, 2021, 23, 64.	1.6	9
77	Autoantibodies and Cancer Association: the Case of Systemic Sclerosis and Dermatomyositis. Clinical Reviews in Allergy and Immunology, 2022, 63, 330-341.	2.9	8
78	Risk of Digital Vascular Events in Scleroderma Patients Who Have Both Anticentromere and Anti–Interferonâ€Inducible Protein 16 Antibodies. Arthritis Care and Research, 2017, 69, 922-926.	1.5	7
79	Granzyme B Induces IRF-3 Phosphorylation through a Perforin-Independent Proteolysis-Dependent Signaling Cascade without Inducing Cell Death. Journal of Immunology, 2021, 206, 335-344.	0.4	6
80	<scp>Antiâ€Cortactin</scp> Autoantibodies Are Associated With Key Clinical Features in Adult Myositis But Are Rarely Present in Juvenile Myositis. Arthritis and Rheumatology, 2022, 74, 358-364.	2.9	6
81	Stem cells in inflammatory disease. Current Opinion in Rheumatology, 2006, 18, 618-619.	2.0	5
82	[7] Immunoblotting of single cell types isolated from frozen sections by laser microdissection. Methods in Enzymology, 2002, 356, 70-79.	0.4	4
83	Histidyl–transfer RNA synthetase: A key participant in idiopathic inflammatory myopathies. Arthritis and Rheumatism, 2011, 63, 331-333.	6.7	4
84	A Bayesian approach to restricted latent class models for scientifically structured clustering of multivariate binary outcomes. Biometrics, 2021, 77, 1431-1444.	0.8	4
85	Expression of the Autoantigen Topoisomeraseâ€1 is Enriched in the Lung Tissues of Patients With Autoimmune Interstitial Lung Disease: A Case Control Study. ACR Open Rheumatology, 2020, 2, 657-661.	0.9	4
86	Advances at the interface of cancer and systemic sclerosis. Journal of Scleroderma and Related Disorders, 2021, 6, 50-57.	1.0	4
87	Accuracy of commercial panels to evaluate myositis autoantibodies: A single-institution perspective. Journal of the American Academy of Dermatology, 2021, 84, 572-574.	0.6	4
88	Presence and Implications of <scp>Antiâ€Angiotensin Converting Enzymeâ€2</scp> Immunoglobulin M Antibodies in <scp>Antiâ€Melanomaâ€Differentiationâ€Associated</scp> 5 Dermatomyositis. ACR Open Rheumatology, 2022, 4, 457-463.	0.9	4
89	Estimating autoantibody signatures to detect autoimmune disease patient subsets. Biostatistics, 2019, 20, 30-47.	0.9	3
90	Antiâ€retinoblastoma Protein Antibodies: A New Specificity in Systemic Lupus Erythematosus Associated With Protection Against Lupus Nephritis. ACR Open Rheumatology, 2019, 1, 287-291.	0.9	2

#	Article	IF	CITATIONS
91	Pilot study to determine whether transient receptor potential melastatin type 8 (TRPM8) antibodies are detected in scleroderma. Clinical and Experimental Rheumatology, 2015, 33, S123-6.	0.4	2
92	The Autoimmune Myopathies. , 2014, , 547-554.		1
93	Macromolecular substrates for the ICE-like proteases during apoptosis. , 1997, 64, 50.		1
94	Autoantigens as Substrates for Apoptotic Proteases: Implications for the Pathogenesis of Systemic Autoimmune Disease. , 0, , 243-260.		0
95	Self-antigen Modification and Autoimmunity. , 2006, , 139-156.		0
96	Reply. Arthritis Care and Research, 2017, 69, 454-454.	1.5	0
97	Reply. Arthritis and Rheumatology, 2017, 69, 1915-1916.	2.9	0
98	4â $€$ Anti-retinoblastoma protein antibodies are negatively associated with lupus nephritis. , 2019, , .		0
99	The Autoimmune Myopathies. , 2020, , 703-713.		0
100	Anti-ANP32A antibodies in systemic sclerosis. Annals of the Rheumatic Diseases, 2021, , annrheumdis-2021-221354.	0.5	0